SYMPOSIUM 14: Target Concentrations, Time to Reach Target, Days in Target: Therapeutic Target Parameters
Tracks
Track 2
| Tuesday, September 23, 2025 |
| 3:30 PM - 5:00 PM |
| Grand Copthorne Waterfront Hotel - Waterfront Ballroom I |
Details
Attainment of anti-infective concentrations within therapeutic range is widely accepted as the outcome of Therapeutic Drug Monitoring (TDM). Several randomized control trials considering the achievement of therapeutic range as the outcome of TDM intervention could not demonstrate any advantage or could demonstrate only a marginal advantage of TDM strategies in improving clinical outcomes. Inclusion of time to reach target and days in target as parameters of therapeutic target in addition to attainment of target concentrations may considerably improve patient outcome. This symposium will explore strategies to achieve these three goals of TDM and will suggest how to integrate all these goals as an intervention while performing clinical trials.
Speaker
Lee Lee Low
Hospital Sultanah Bahiyah
The impact of Inter-individual variation of anti-infective drug exposure and delay in achieving target anti-infective drug concentrations on clinical outcome
Biography
Dr Anne-Grete MÃrtson
University of Leiden
Use of dose optimization programs in achieving target anti-infective drug concentrations early and maintaining it for the duration of anti-infective drug treatment
Biography
Prof Birgit Koch
Erasmus MC Rotterdam
Strategies to Improve Therapeutic Target Attainment for Anti-Infectives: Leveraging Advanced Tools and Technologies
Abstract
Achieving optimal therapeutic target attainment in anti-infective therapy is essential for maximizing efficacy, reducing toxicity, and minimizing the development of resistance. This session will explore innovative strategies that aim to improve the precision of anti-infective dosing through the integration of advanced technologies and methodologies.
Goals/Objectives:
1. Understand the Role of Therapeutic Drug Monitoring (TDM) in individualizing dosing and improving patient outcomes by adjusting drug levels for optimal therapeutic response.
2. Explore Model-Informed Precision Dosing (MIPD) as a cutting-edge approach to predict individualized drug doses based on pharmacokinetic (PK) models and patient-specific data, ensuring better efficacy and safety.
3. Examine the Importance of Target Site Concentrations in achieving effective drug exposure at the site of infection, highlighting the need for enhanced PK models that incorporate tissue penetration data.
4. Discuss Alternative Sampling Techniques such as saliva and dried blood spots, offering less invasive and more frequent options for monitoring anti-infective drug concentrations.
5. Delve into the Potential of Improved PK Models and how they can provide more accurate dosing recommendations through population-based approaches and dynamic modeling.
6. Review the Future of Machine Learning and Real-Time Monitoring, which could revolutionize anti-infective therapy by enabling continuous, real-time dosing adjustments based on patient-specific data.
By the end of this session, participants will gain a comprehensive understanding of the evolving landscape of anti-infective therapy, equipped with the tools necessary to implement these advanced strategies to optimize therapeutic target attainment.
Goals/Objectives:
1. Understand the Role of Therapeutic Drug Monitoring (TDM) in individualizing dosing and improving patient outcomes by adjusting drug levels for optimal therapeutic response.
2. Explore Model-Informed Precision Dosing (MIPD) as a cutting-edge approach to predict individualized drug doses based on pharmacokinetic (PK) models and patient-specific data, ensuring better efficacy and safety.
3. Examine the Importance of Target Site Concentrations in achieving effective drug exposure at the site of infection, highlighting the need for enhanced PK models that incorporate tissue penetration data.
4. Discuss Alternative Sampling Techniques such as saliva and dried blood spots, offering less invasive and more frequent options for monitoring anti-infective drug concentrations.
5. Delve into the Potential of Improved PK Models and how they can provide more accurate dosing recommendations through population-based approaches and dynamic modeling.
6. Review the Future of Machine Learning and Real-Time Monitoring, which could revolutionize anti-infective therapy by enabling continuous, real-time dosing adjustments based on patient-specific data.
By the end of this session, participants will gain a comprehensive understanding of the evolving landscape of anti-infective therapy, equipped with the tools necessary to implement these advanced strategies to optimize therapeutic target attainment.
Biography
Birgit CP Koch is Hospital Pharmacist-Clinical Pharmacologist and Full Professor of Clinical Pharmacometrics, working at Erasmus MC in Rotterdam. She supervises the education program for residents in Clinical Pharmacology.
Nowadays, she is member of the executive board of EPASG, the PK/PD group of ESCMID, council member of IATDMCT, member the pharmacology committee of UEMS, the specialist registration committee for hospital pharmacists and clinical pharmacologists in the Netherlands, member of ISAP, ASCPT, EACPT, the SWAB committee, the medical ethical board, the editorial board of therapeutic drug monitoring, British Journal of Clinical Pharmacology and Clinical Pharmacokinetics. She is member of the alternative sampling and infections committees of IATDMCT and NWO VIDI member. She is chair of the Young Investigator Grant Committee and chair of the expert team Knowledge security of Erasmus MC.
She authored > 230 publications on PK/PD, TDM and toxicology and she is the PI of several studies on model-based dosing, TDM and PK in antibiotics and psychoactive drugs, with funding > 2000 K. Her research focuses on alternative matrices, pharmacokinetics and pharmacodynamics of drugs in special populations and toxicology during pregnancy. At the moment, she supervises 21 PhD students (and 9 finished).
Dr Vikram Gota
Advanced Centre For Treatment, Research and Education in Cancer, Tata Memorial Centre, Mumbai
How to perform clinical trials with TDM as an interventional strategy?
Biography
Session chair
Sophie Stocker
The University Of Sydney
